Loading...
NPI 1538507819 · Glen Allen, VA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rca Laboratory Services, LLC is a clinical medical laboratory provider located in Glen Allen, Virginia. This profile covers 129 Medicare and 82 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rca Laboratory Services, LLC |
| Address | 4060 Innslake Dr |
| City | Glen Allen |
| State | VA |
| ZIP | 23060 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 10, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $17.1M |
| Medicare | $5.3M |
RCA LABORATORY SERVICES, LLC reports materially more Medicaid revenue than Medicare: total Medicaid revenue is $17.1M while total Medicare revenue is $5.3M, indicating Medicaid is the provider’s primary payer source on file. This makes the provider effectively Medicaid‑heavy in scale rather than a balanced dual‑payer operation.
Medicare revenue is highly concentrated in molecular amplified probe testing: the top three Medicare codes (87798, 87150, 87481) account for 72.4% of the provider’s Medicare revenue, with 87798 generating $1.7M (35.3%), 87150 $1.2M (24.1%), and 87481 $644.5K (13.0%). These codes are all amplified nucleic acid probe techniques or organism characterization tests, which points to a service line centered on high-volume molecular infectious‑disease diagnostics.
Medicaid revenue is overwhelmingly driven by high‑throughput SARS‑CoV‑2 testing: U0003 alone represents $14.3M (84.6%) of the provider’s $17.1M Medicaid revenue and 303.9K claims, and the top three Medicaid codes together account for 94.2% of Medicaid revenue. This concentration signals that large-scale COVID PCR testing underpins the company’s Medicaid business.
The provider is a state‑level dominant player for COVID testing on Medicaid: U0003 ranks #1 of 111 in‑state (100th percentile; extreme outlier, far above typical state volume) and U0005 ranks #2 of 80 (99th percentile; extreme outlier), indicating market leadership in high‑throughput SARS‑CoV‑2 testing within Virginia. That in‑state dominance contrasts with its Medicare profile, where leadership is more mixed across several molecular test codes.
Nationally on Medicare the practice shows elevated specialty volume for several molecular codes: 87798 ranks #37 of 1319 providers (97th percentile; notably above typical national volume) and 87481 ranks #23 of 1117 providers (98th percentile; notably above typical national volume). Additionally, 87150 ranks #14 of 190 (93rd percentile; typical) and 86343 is an extreme national outlier (ranks #1 of 21, 100th percentile), together suggesting pockets of unusually high national activity in selected niche assays alongside more typical volumes for common lab panels.
Operational footprint appears to include both high‑throughput molecular testing and routine clinical lab work: Medicare claim counts include large‑volume procedural codes such as 87798 (51.4K claims), 87150 (35.2K claims), and specimen collection 36415 (12.3K claims), while Medicaid activity includes substantial instrumented drug screening (80307, 32.5K claims) and multiple pharmacogenomic/CYP tests (81226, 81225, 81230, 81231 listed among top Medicaid codes). This mix indicates a centralized laboratory that combines mass molecular diagnostics with standard clinical and specialized genetic testing services.
The provider has an established presence with NPI enumeration dated 2013-06-10 (~13 years ago), supporting that the observed high volumes represent sustained operations rather than a very recent start‑up surge. Tenure combined with extremely high Medicaid COVID volumes suggests long‑standing capacity that was scaled for pandemic testing demand.
Given the extreme revenue concentration—72.4% of Medicare revenue tied to three molecular codes and 94.2% of Medicaid revenue tied to three codes—this profile implies concentration risk and strategic dependence on a small set of services. For payers and network analysts, those concentrations (especially the Medicaid U0003 dominance) are relevant for contract negotiations, capacity planning, and specialty network composition because shifts in reimbursement, testing demand, or contracting could disproportionately affect the provider’s revenue base.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
129 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 51,450 | $30 | $1.7M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 35,190 | $30 | $1.2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 18,960 | $30 | $644.5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,760 | $70 | $204.5K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 4,230 | $30 | $143.8K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 3,120 | $30 | $105.9K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 3,100 | $30 | $105.3K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 8,380 | $10 | $100.6K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 12,300 | $10 | $98.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 7,620 | $10 | $76.2K |
Showing 1–10 of 129
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 129 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
82 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 303,860 | $50 | $14.3M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 32,490 | $30 | $1.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 43,440 | $10 | $521.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,160 | $80 | $162K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 3,570 | $30 | $92.9K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 1,750 | $40 | $66.7K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 810 | $80 | $65K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 340 | $180 | $59.8K |
| 82570 | The lab analyst measures the amount of creatinine, in a patient specimen, other than blood. Creatinine is the waste material generated by the muscle tissue produced from the breakdown of creatine… | 28,820 | $1 | $57.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 3,020 | $20 | $57.3K |
Showing 1–10 of 82
How this provider's Medicaid billing volume and revenue compare to other Virginia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Virginia median
82 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 10 | 170 | 3,790 | $40 | $415.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 23 | 20 | 1,790 | $70 | $347.5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 110 | 1,150 | $40 | $331.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 71 | 100 | 2,220 | $40 | $214.2K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 6 | 20 | 350 | $30 | $170.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 136 | 230 | 5,240 | $1 | $93.2K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 59 | 90 | 380 | $50 | $76.5K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 20 | 30 | 150 | $70 | $69K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 16 | 60 | 430 | $20 | $62.8K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 14 | 50 | 760 | $10 | $55.4K |
Showing 1–10 of 82
Other providers in the same ZIP code as Rca Laboratory Services, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.